Lps induces IL-6 in the brain and in serum largely through TNF production.
暂无分享,去创建一个
P. Ghezzi | S. Sacco | R. Bertini | D. Agnello | G. Caselli | A. Marullo
[1] F. Breedveld,et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.
[2] P. Ghezzi,et al. Differential contribution of R and S isomers in ketoprofen anti-inflammatory activity: role of cytokine modulation. , 1998, The Journal of pharmacology and experimental therapeutics.
[3] M. Feldmann,et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. , 1997, British journal of rheumatology.
[4] P. Ricciardi-Castagnoli,et al. Differential effects of IL-6 on systemic and central production of TNF: a study with IL-6-deficient mice. , 1997, Cytokine.
[5] N. Topley,et al. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. , 1997, Cytokine.
[6] W. Fiers,et al. TNF receptor p55 plays a major role in centrally mediated increases of serum IL-6 and corticosterone after intracerebroventricular injection of TNF. , 1996, Journal of immunology.
[7] P. Ricciardi-Castagnoli,et al. Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production , 1996, Brain Research.
[8] C. Hack,et al. Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha. , 1996, Journal of immunology.
[9] P. Isakson,et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. , 1996, The Journal of clinical investigation.
[10] E. Shacter,et al. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Willatts,et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.
[12] M. Feldmann,et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. , 1995, European cytokine network.
[13] G. Fantuzzi,et al. Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice , 1995, Infection and immunity.
[14] A. Mantovani,et al. Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. , 1992, International journal of immunopharmacology.
[15] J. M. Lipton,et al. Central administration of the peptide α-MSH inhibits inflammation in the skin , 1991, Peptides.
[16] R. Danner,et al. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents , 1991, The Journal of experimental medicine.
[17] B. Echtenacher,et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.
[18] R. Strieter,et al. Dynamics of dibutyryl cyclic AMP- and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression , 1989, Infection and immunity.
[19] M. Feldmann,et al. INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.
[20] A. Mantovani,et al. IL-1 stimulates IL-6 production in endothelial cells. , 1989, Journal of immunology.
[21] D. Gemsa,et al. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. , 1988, Journal of immunology.
[22] J. Vilček,et al. Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. , 1988, The Journal of biological chemistry.
[23] D. Remick,et al. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. , 1988, The Journal of biological chemistry.
[24] C. Dinarello. The biology of interleukin 1 and comparison to tumor necrosis factor. , 1987, Immunology letters.
[25] A. C. Webb,et al. Multiple biological activities of human recombinant interleukin 1. , 1986, The Journal of clinical investigation.
[26] D. Goeddel,et al. Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.
[27] F. Kuehl,et al. The diminished production of arachidonic acid oxygenation products by elicited mouse peritoneal macrophages: possible mechanisms. , 1980, Journal of immunology.
[28] T. Haley,et al. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. , 1957, British journal of pharmacology and chemotherapy.